Today, clinicians rely on a liver biopsy to identify and diagnose non-alcoholic steatohepatitis (NASH). In order to improve the management of patients, the development of a non-invasive screening tool appears to be necessary. That is why DIAFIR and hepatologists at the CHU of Angers are working together to clinically validate a non-invasive NASH test, based on […]
Breakthrough serum diagnostic for NASH and other diseases
French Photonic Day
Bercy, Ministry of Industry
Mid-infrared light biosensor
Where mid-infrared spectroscopy meets medicine
RENNES, FRANCE — March, 29 2019 — DIAFIR, a medical technology company focused on the development, manufacture and sale of innovative diagnostic solutions in nonalcoholic steatohepatitis (NASH) and septic arthritis announces today the appointment of Mr Richard Guillaume to its Board of Directors Mr Guillaume has a wide experience of over 30 years in international […]
DIAFIR has been incepted in 2011 by a world-renowned team of researchers from Rennes 1 University, France.
DIAFIR has developed the SPID™ platform, a breakthrough proprietary device for patient screening triage. SPID™ analyses the entire metabolic signature spectrum of patient’s blood serum, within minutes, using mid-infrared spectroscopy.
Thanks to its platform, DIAFIR aims to develop and bring to market its revolutionary serum test NASHMIR® for NASH detection.
Our goal is to help save lives through early detection while being minimally invasive to the patient.
- DIAFIR’s vision is to become the standard of care in the way people are routinely checked for NASH (early detection).
- DIAFIR’s method is easy to implement and at a low cost, currently targeting the obese patients as the first choice for NASH detection.
- Our proprietary platform SPID™ can be applied on other types of diseases (as a start we are focused on NASH and infectious arthropathies).